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Valproic acid influences 
the expression of genes implicated 
with hyperglycaemia‑induced 
complement and coagulation 
pathways
Marina Barreto Felisbino1,2,7, Mark Ziemann2,7, Ishant Khurana2, Jun Okabe2, 
Keith Al‑Hasani2, Scott Maxwell2, K. N. Harikrishnan2, Camila Borges Martins de Oliveira1, 
Maria Luiza S. Mello1 & Assam El‑Osta2,3,4,5,6*
Because the liver plays a major role in metabolic homeostasis and secretion of clotting factors and 
inflammatory innate immune proteins, there is interest in understanding the mechanisms of hepatic 
cell activation under hyperglycaemia and whether this can be attenuated pharmacologically. We 
have previously shown that hyperglycaemia stimulates major changes in chromatin organization and 
metabolism in hepatocytes, and that the histone deacetylase inhibitor valproic acid (VPA) is able to 
reverse some of these metabolic changes. In this study, we have used RNA‑sequencing (RNA‑seq) to 
investigate how VPA influences gene expression in hepatocytes. Interesting, we observed that VPA 
attenuates hyperglycaemia‑induced activation of complement and coagulation cascade genes. We 
also observe that many of the gene activation events coincide with changes to histone acetylation at 
the promoter of these genes indicating that epigenetic regulation is involved in VPA action.
Diabetes mellitus is a multifactorial disorder with several pathways implicated in the development of diabetic 
micro- and macro-vascular  complications1. Macrovascular complications include atherosclerosis, cerebrovas-
cular disease and peripheral vascular disease; for which diabetic patients have a two- to four-fold greater risk 
than non-diabetic  individuals2. In diabetes, a combination of hyperglycaemia, inflammation, oxidative stress 
and insulin resistance converge to produce a prothrombotic milieu, characterised by endothelial dysfunction, 
coagulative activation and platelet hyperreactivity, reviewed  in3.
Several important coagulation pathway proteins are elevated by hyperglycaemia in vivo including fibrinogen, 
prothrombin 1 and 2, tissue factor, thrombin-antithrombin complexes, plasminogen activator inhibitor-1, tissue 
plasminogen activator and complement C3 which contribute to this hypercoagulative  state4–6. This prothrombotic 
state co-exist with chronic low-grade inflammation and oxidative  stress7. Complement cascade proteins are a pro-
posed source of inflammation in diabetes that are produced by monocytes, macrophages and hepatocytes. These 
proteins function in innate antimicrobial defense primarily through membrane attack and phagocyte recruit-
ment that are elevated in diabetes and suspected to contribute to diabetic  complications8. The liver is the main 
site of production of circulating coagulation and complement proteins, also responsible for production of bile, 
cholesterol, decomposition of red blood cells and detoxification of xenobiotics and secondary  metabolites9–12. Of 
key importance for diabetes, liver hepatocytes play a major role in energy homeostasis by storing carbohydrates 
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as glycogen during hyperglycaemia and releasing sugars during hypoglycemia. Liver dysfunction, classified as 
elevated hepatic glucose production during hyperglycaemia, is common in type-2 diabetes, and inhibiting this is 
a major mechanism of action of the widely prescribed glucose lowering drug  metformin13. Thus, understanding 
the molecular mechanisms underpinning the hyperglycaemic activation of metabolism, coagulation, comple-
ment and other inflammatory pathways in hepatocytes could identify new therapies to reduce the burden of 
diabetic complications.
At the interface between genetic and environmental factors, epigenetic mechanisms are proposed to play 
a major role in the development of metabolic disease including diabetic  complications14,15. Previous reports 
have demonstrated that chromatin remodeling and histone acetylation are important mechanisms in diabetes 
 development16,17. The epigenetic component of metabolic/inflammatory disorders has come recently to attention, 
revealing epigenetic drugs as potential immunomodulatory agents. The recent discovery that histone deacetylase 
(HDAC) inhibitors (HDACi) have the ability to reduce the severity of inflammatory and autoimmune diseases, 
including diabetes, in several animal models, has positioned them as alternative anti-inflammatory  agents18–21. 
Their paradigmatic mode of action has been defined as increased histone acetylation of target genes, leading to 
higher gene expression; however, recent studies have shown a more diverse mechanism of gene  regulation22–25.
Valproic acid (VPA; IUPAC: 2-propylpentanoic acid), the most clinically prescribed HDACi, is a fatty acid 
with anticonvulsant properties used for the treatment of epilepsy and  seizures26. VPA inhibits class I (HDAC1, 
HDAC2, HDAC3, HDAC8) and class IIa (HDAC4, HDAC5, and HDAC7), leading to an increase in the acetyla-
tion of histones H2, H3, and H4, which modify the expression of associated  genes21. Recently, its use has been 
investigated associated with different diseases as a strategy of repurposing clinically approved  drugs27–29. There 
are reports of VPA reducing the blood glucose level and fat deposition in adipose tissue and liver of mice and 
 rats30,31, while Class  I32,33 and class  IIa34 HDACs seems to be involved in the control of gluconeogenesis signaling 
and the insulin production. VPA also reduces the microvascular complications of  diabetes35,36.
We have previously shown that treatment of HepG2 human hepatocytes with the HDACis Trichostatin A 
(TSA) and VPA attenuated hepatic glucose production, although no significant difference was detected in global 
chromatin structure and epigenetic landscape. Chromatin alterations promoted by HDACi under hyperglycaemia 
may be a function of the differently regulated nuclear domains and genes rather than of global  remodeling17. 
Therefore, identification of genes influenced by HDAC inhibition is paramount to understanding of its mecha-
nisms of action and therapeutic target in amelioration of hyperglycaemic  state23. We hypothesise that hepato-
cytes undergo major gene expression alterations when exposed to a hyperglycaemic environment as the liver 
is an organ of critical importance to carbohydrate metabolism. Furthermore, we hypothesised that VPA could 
attenuate some of the deleterious pathways promoted by hyperglycaemia by conferring changes to promoter 
histone acetylation.
In this study, HepG2 cells exposed to high-glucose (HG) were stimulated with VPA. We performed high 
throughput RNA-sequencing (RNA-seq) to understand transcriptome-wide analysis of genes and pathways 
in response to hyperglycaemia and VPA. We observe genes influenced by VPA are altered in H3K9ac at their 
promoters. This work identified that complement and coagulation pathways activated by hyperglycaemia were 
attenuated by HDAC inhibition.
Results
Hyperglycaemia regulates hepatocyte gene expression. In order to understand the effect of high 
glucose on whole genome hepatic gene expression, RNA-seq was performed on HepG2 cells cultured under 
continuous low glucose (LG) or stimulated with 48 h high glucose (HG; 20 mM) in triplicate. After read align-
ment and gene expression quantification, differential expression analysis of genes and pathways was undertaken. 
Multidimensional scaling analysis measures the similarity of the samples and projects this on two-dimensions. 
We observed that LG and HG samples clustered into distinct groups (Fig.  1A). Statistical analysis showed 
that HG treatment had a strong effect on HepG2 cells, with 4259 genes (26%) showing differential expression 
(FDR ≤ 0.05; Fig. 1B—red points). This effect in gene expression is greater than that reported previously for high 
glucose treated THP-1 human monocytic cell  line37 and skeletal muscle of diabetic Goto–Kakizaki when com-
pared to control Wistar  rat38 suggesting that hepatic cells are especially sensitive to alterations in glucose level. 
The top 50 differentially expressed genes by significance are shown in heatmap form (Fig. 1C). Some of the genes 
influenced by HG are also highlighted in Table 1.
Gene Set Enrichment Analysis (GSEA) was used in order to understand pathways regulated by hyper-
glycaemia. From 575 REACTOME gene sets considered, 34 were upregulated and 139 were down-regulated 
(FDR ≤ 0.05). The top 20 gene sets by significance in the up and down-regulated directions are shown (Fig. 2A). 
Down-regulated gene sets included those associated with extracellular matrix interactions, chaperone function, 
calnexin/calreticulin cycle, N-glycan trimming and peptide chain elongation (Fig. 2A), while gene sets upregu-
lated in response to hyperglycaemia included cholesterol biosynthesis, complement cascade and fibrin clotting 
cascade (Fig. 2B–D). These findings show a distinctive severe response of hepatocytes to hyperglycaemia.
VPA treatment influences the expression of hyperglycaemic response genes. Given that hyper-
glycaemia induces changes to the hepatocyte transcriptome and activates pathways relevant to cardiovascular 
health (such as cholesterol metabolism and complement/clotting cascades) and our previous work shows that 
VPA attenuates hepatic function, we hypothesised that VPA might inhibit hyperglycaemic gene expression sig-
natures. To resolve this, cells under LG and HG conditions for 48 h were exposed to 1.0 mM VPA for a further 
12 h. The gene expression profiles were compared to the respective controls without VPA. Quantitative analy-
sis of histone H3K9/14ac protein using LI-COR Odyssey imaging system show significant hyperacetylation in 
response to VPA (Fig. 3A).
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Figure 1.  RNA-seq identifies gene expression changes due to high glucose exposure in HepG2 cells. (A) 
Multidimensional scaling analysis shows sample clustering based upon treatment. (B) Smear plot depicts 
the log2 fold change and average expression level log2 counts per million for each detected gene. Genes with 
differential expression (FDR ≤ 0.05) are highlighted in red. (C) Heatmap of the 50 most significant differentially 
expressed genes. LG, low glucose—normoglycemic condition. HG, high glucose—hyperglycaemic condition.
Table 1.  Selected genes differently regulated by hyperglycaemia exposure in HepG2 cells. FDR, false discovery 
rate.
Gene Function Log2 fold change FDR
TXNIP A known hyperglycaemia inducible gene that is highly abundant in HepG2 cells. TXNIP protein inhibits the normal function of thioredoxin leading to accumulation of ROS 5.38 2.99E−45
SERPING1 Encodes C1 esterase inhibitor and is involved in inhibition of complement cascade 2.17 6.72E−45
MPZ Encodes a structural component of the myelin sheath and is thought to be specific to nervous system tissues 1.70 2.61E−29
MSMO1 Encodes a protein involved in cholesterol biosynthesis 1.76 2.09E−25
PCSK9 Protein acts binding to and degrading low-density lipid receptors 1.93 4.85E−20
IGF2 Encodes an insulin-like growth factor, the central regulator of somatic growth and cell proliferation 1.13 4.81E−18
MANF Protein promotes survival of dopaminergic neurons, possibly playing a role in ER stress response − 2.75 3.41E−64
HSPA5
(aka GRP78) Encodes a glucose sensing protein, whose expression is upregulated by glucose starvation and is also present in the ER − 2.04 1.93E−45
CALR Encodes calreticulin, a major calcium storage protein in the ER − 2.23 9.49E−40
DNAJB11 Encodes a ER localized protein that acts as a chaperone for a number of partners − 2.12 1.65E−36
SLC2A1 The glucose transporter gene that encoding GLUT1 − 1.19 1.20E−20
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Multidimensional scaling analysis shows that samples cluster based on treatment group. Untreated samples 
(LG, HG) are clearly separated from VPA-treated samples (LGV, HGV); and normoglycemic samples (LG, LGV) 
are separated from hyperglycaemic ones (HG, HGV) (Fig. 3B). Smear plot shows that 7802 genes were altered 
in expression due to VPA treatment under hyperglycaemia (Fig. 3C). This plot also shows genes with initially 
low expression were upregulated after VPA treatment; on the other hand, genes initially highly expressed were 
down-regulated. Heatmap of top 50 genes by significance shows that the majority were upregulated (Fig. 3D) and 
differential gene expression modulated by VPA under normoglycaemic and hyperglycaemic conditions (Fig. 3E).
Next, we sought to identify gene sets altered by VPA in the context of high glucose. The top 20 gene sets 
by significance in the up- and down-regulated directions are shown (Fig. 4A). Gene sets upregulated included 
those related to function of neurons including potassium channels, neurotransmitter receptor, L1-type/ankyrins 
interactions. Down-regulated gene sets included common pathway of fibrin clot formation, complement cascade 
and genes involved in protein synthesis. Clotting and complement cascade genes were down-regulated by VPA 
in hyperglycaemic condition (Fig. 4B,C). The regulation of all genes in response to glucose and VPA was visu-
alised on a two dimensional rank–rank plot (Fig. 4D). We observe that overall, genes are distributed relatively 
evenly among the four quadrants. Using rank–rank visualisation of clotting and complement cascade genes we 
observed coordinated upregulation of these genes with hyperglycaemia and attenuation by VPA (Fig. 4E,F). The 
FDR corrected MANOVA p values for the two-dimensional association were 2.0E−4 and 1.5E−7 for clotting and 
complement cascades respectively.
To validate some of the differentially expressed genes from the RNA-seq findings, we cultivated HepG2 cells 
under hyperglycaemic conditions prior to treatment with VPA as above described followed by quantitative reverse 
Figure 2.  GSEA identifies differentially expressed REACTOME pathways in response to high glucose. (A) 
Top 20 up- and down-regulated pathways selected by statistical significance. (B–D) Enrichment plots show 
upregulation of cholesterol biosynthesis, complement cascade and common clotting cascade in response to 
hyperglycaemia. Beside each enrichment plot, we have included a list of genes that contribute to the enrichment 
(“leading edge”). GSEA FDR < 0.05 for all pathways shown.
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Figure 3.  Effect of VPA stimulation on hyperglycaemic HepG2 gene expression. (A) VPA induces H3 acetylation in a time-
dependent manner. Quantitative analysis of H3K9/14ac and unmodified histone H3 protein using LI-COR Odyssey imaging 
system. Normoglycaemic HepG2 cells treated with 1 mM VPA in comparison with untreated control. (B) Multidimensional 
scaling analysis shows samples cluster based upon treatment groups. (C) Smear plot showing the effect of VPA treatment 
on hyperglycaemic HepG2 cells. Genes with differential expression (FDR ≤ 0.05) are highlighted in red. (D) Heatmap of the 
50 most significant differentially expressed genes responding to VPA. LG, low glucose—normoglycemic condition. LGV, 
normoglycemic condition followed by VPA treatment. HG, high glucose—hyperglycaemic condition. HGV, hyperglycaemic 
condition followed by VPA treatment. (E) Venn diagram showing gene expression changes regulated by VPA under 
normoglycaemic and hyperglycaemic conditions.
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transcription PCR (RT-qPCR). The selected genes included those involved in the complement (MASP2 and C3) 
pathway. Selected genes upregulated by hyperglycaemia according to the RNA-seq results, and confirmed by 
real-time PCR, were attenuated by VPA stimulation in agreement with RNA-seq (Fig. 5). As proof of concept, 
we assessed the relative abundance of H3K9ac at the promoter of the MASP2 and C3 genes using chromatin 
immunoprecipitation (ChIP) and qPCR detection. We observe reduced H3K9ac in VPA treated cells and under 
hyperglycaemic conditions H3K9ac is partly attenuated suggesting hyperglycaemia-induced expression of com-
plement and clotting genes could be regulated by histone acetylation.
Discussion
The metabolic syndrome and associated cardiovascular complications are a major health burden. There is lim-
ited information on how hyperglycaemia influences gene regulation. Because the liver plays a major role in 
energy homeostasis, we hypothesised that hepatocytes show robust gene expression changes in response to 
Figure 4.  VPA attenuates expression of clotting and complement pathways in hyperglycaemic HepG2 cells. 
(A) Top 20 REACTOME pathways with differential expression in response to VPA under hyperglycaemia 
determined with ranked gene set enrichment analysis (GSEA-P, FDR < 0.05). (B,C) Enrichment plot shows 
downregulation of common clotting and complement cascades in response to VPA. (D) Rank-rank plots of 
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hyperglycaemia, some of which could be deleterious to cardiovascular health. Furthermore, we hypothesised 
that HDAC inhibition via VPA could reverse or attenuate some of these gene pathways.
We used high throughput RNA sequencing (RNA-seq) for its unbiased ability to detect expressed genes 
with greater sensitivity and accuracy than gene expression microarrays. With appropriate bioinformatics tools, 
regulatory events to genes and pathways (sets of genes) can be pinpointed in a way that is more efficient than 
single-gene assays. These tools were applied to identify genes and pathways that respond to hyperglycaemia and/
or VPA in hepatocytes.
The major gene sets upregulated by hyperglycaemia were related to cholesterol metabolism, DNA replication 
and complement cascade and clotting cascades. The observation of elevated expression of clotting and comple-
ment factors is consistent with reports of these proteins being elevated in patients with diabetes. Interestingly, 
of these pathways, only complement and clotting cascades were attenuated by VPA.
The complement system is central to innate immunity against microorganisms and modulator of inflam-
matory processes; it comprises a complex and tightly regulated group of proteins involving various soluble and 
surface-bound components. Depending on the activation trigger, the complement cascade follows one of three 
pathways: classical, lectin or  alternative39. Although these pathways differ in their mechanisms of target recog-
nition, all converge in the activation of the central component C3. This process is followed by C5 cleavage and 
the assembly of the pore-like membrane attack complex, MAC. Important chemoattractants and inflammatory 
mediators are produced by the enzymatic cleavage of C3 and C5, which leads to the release of anaphylatoxins 
C3a and  C5a40.
The coagulation system is another major blood-borne proteolytic  cascade41. Upon activation of the coagu-
lation cascade, a sequential series of serine protease-mediated cleavage events occur. Thrombin is activated 
from its zymogen prothrombin and then catalyze the polymerization of fibrin by cleaving small peptides from 
its subunits. This way, soluble fibrinogen is converted into insoluble fibrin, which allows the clot  formation42. 
Thrombin also plays a key role in amplifying the cascade by feedback activation of coagulation  factors43. Other 
Figure 5.  Validation of complement pathway gene (MASP2, C3) RNA expression and promoter H3K9ac 
enrichment. VPA stimulation attenuates the expression of these genes and is consistent with changes in 
promoter H3K9ac. LG, low glucose—normoglycemic condition. LGV, normoglycemic condition followed by 
VPA treatment. HG, high glucose—hyperglycaemic condition. HGV, hyperglycaemic condition followed by 
VPA treatment. *p < 0.05; **p < 0.01; ***p < 0.001 as determined by one-way anova analysis.
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components such as circulating red and white blood cells and platelets are incorporated into the clot structure. In 
addition, factor XIIIa, which is also activated by thrombin, provides further structural stability by cross-linking 
with  fibrin44. In this context, weak clots are more susceptible to fibrinolysis and bleeding, while resistant clots 
may promote  thrombosis42.
Coagulation and complement cascades share a common evolutionary  origin41 and their interplay is high-
lighted by C3, C4, C5a and FB complement protein presence in  thrombus45. Similarly, pro-coagulation enzymes 
thrombin and IXa, Xa, XI factors might activate complement  cascade46. Moreover, MASP2, a component of lectin 
complement activation, is capable of cleaving coagulation factors prothrombin in thrombin, fibrinogen, factor 
XIII and thrombin-activatable fibrinolysis inhibitor in vitro47,48. Thus, understanding the crosstalk between these 
pathways has fundamental clinical implications in the context of diseases with an inflammatory and thrombotic 
pathogenesis, in which complement–coagulation interactions contribute to the development of  complications49.
Liver, mainly hepatocytes, is responsible for the biosynthesis and secretion of the majority of complement 
and coagulation components. Furthermore, the promoter regions of these components are controlled by several 
common liver-specific transcription factors like HNFs and C/EBP50. Thomas and co-workers51 compared the 
genome-wide binding of Fxr and Hnf4α in mouse liver and characterized their cooperative activity on binding 
to and activating target gene transcription. Genes bound by Fxr and Hnf4α are enriched in complement and 
coagulation cascades, as well as in pathways related to drug metabolism. Furthermore, these transcription factors 
are involved in gluconeogenesis and glycogenolysis gene  regulation52,53. Thus, a common transcription factor 
network may be controlling these immune and metabolic pathways.
The participation of complement in metabolism and metabolic disorders has recently received increasing 
scientific attention. Earlier studies demonstrate higher plasma C3 levels in diabetic patients compared to healthy 
 individuals6,54. Increased complement gene expression has also been associated with adipocyte insulin resistance, 
waist circumference, and triglyceride  levels55,56. MASP-1 and MASP-2 levels were significantly higher in children 
and adults with T1DM than in their respective control groups, whereas these proteins levels decreased when 
glycemic control  improved57. In a recent study it was reported that in a murine model of diabetic nephropathy, 
genetic knock-out or pharmacological blockade of complement component 5a receptor 1 (C5ar1) conferred 
renal protection and attenuated disease-associated metabolic changes, further reinforcing the importance of 
the complement  pathway58.
Metabolic syndrome, including diabetes mellitus, is associated with a procoagulant state, in which the clotting 
system is switched toward a prothrombotic state, involving reduced fibrinolysis, increased plasmatic coagulation, 
and platelet  hyperactivity43,59,60. Intensive glycemic control with insulin reduces the impact of this procoagulant 
state by affecting components of clotting the  system60. Abnormalities in the coagulation and fibrinolytic systems 
may contribute to the development of cardiovascular complications in patients with metabolic  syndrome43 and 
consistent lowering of clotting factors are used for the treatment of acute cardiovascular  syndromes61.
This study has limitations. The experimental results are derived from transformed HepG2 cells are informative 
but do not replace data derived from primary hepatic cells. Future work is proposed to examine the therapeutic 
benefit of VPA using pre-clinical models of transient and chronic  hyperglycaemia62,63. While, HDAC inhibitors 
such as VPA are associated with changes in gene expression mediated in part by lysine acetylation of histone 
 residues64–70 more recent studies have shown dramatic genome wide histone deacetylation associated with the 
transcription factors, CBP and EP300 using ChIP-Seq in primary vascular  cells23–25,71. The experimental results 
presented in this article suggests lysine acetylation is associated with VPA attenuating MASP and C3 gene expres-
sion we cannot rule out histone deacetylation of other complement genes. Furthermore, in addition to causing 
histone hyperacetylation, VPA has been shown to regulate replication-independent loss of DNA  methylation72 
that is consistent with elevated Tet2 DNA demethylase  enzyme73. This seemingly extends the functional role of 
HDAC inhibitors such as VPA that alter lysine acetylation and deacetylation including DNA methylation by 
extracellular signalling mediated by  hyperglycaemia74.
Several reports in the medical literature demonstrate that patients with neurological conditions taking VPA 
exhibit greater blood loss during surgery, impaired clotting, and reduced concentration of clotting  factors75–78. 
Interestingly, emerging evidence points to complement cascade as having a causal role in some seizure types. 
Micro-array analysis identified complement cascade gene hyperactivation in brain tissue of epilepsy  patients79,80. 
Studies in mice identified complement component C3 as necessary for acute viral infection associated  seizures81. 
Our findings are consistent with these reports and indicate VPA mediated reduction of circulating complement 
and coagulation factors is a result of specific changes in hepatic gene expression. These changes in gene expres-
sion seem to be regulated at least in part by the relative abundance of H3K9ac at their promoter as observed 
here by ChIP qPCR analysis. As a prime initiator and important modulator of immunological and inflammatory 
processes, the complement system has emerged as an attractive target for early and upstream pharmacological 
intervention in inflammatory  diseases82. In this context, repurposing clinically approved drugs such as VPA 
provides a time- and cost-effective alternative.
In conclusion, we could, for the first time, associate HDAC inhibition with complement and coagulation gene 
expression modulation. We demonstrate that coagulation and complement cascade genes were upregulated by 
hyperglycaemia and that these can be attenuated with VPA through its histone acetylation modulation ability. 
Future preclinical studies will resolve whether VPA can mitigate the complications of diabetes in vivo.
Materials and methods
Cell culture. HepG2 cells from ATCC at passage 9 were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) basal glucose (5.5  mM) (Gibco, Carlsbad, USA) supplemented with 10% fetal bovine serum (GE 
Healthcare, Chicago, USA) and penicillin and streptomycin (Gibco) (working dilution: 100 IU and 100 μg/mL, 
respectively). Cells were cultivated for 48 h in normoglycemic (LG 5.5 mM) or hyperglycaemic (HG) medium, 
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containing D-glucose (Sigma, St. Louis, USA) up to a final concentration of 20 mM. Cells under LG and HG 
conditions were then treated with 1.0 mM VPA (Sigma) for another 12 h and compared with the respective 
untreated controls. The experiments were performed using conditions derived for VPA from previous studies 
by our  group64–70.
Transcriptome sequencing. Cells were disrupted with TRIzol (Qiagen, Hilde, Germany). RNA was iso-
lated from TRIzol homogenates using the Direct-zol Kit (Zymo Research, Irvine, USA). RNA was quantified on 
Qubit (Thermo Fisher, Waltham, USA) and its quality was evaluated on the MultiNA bioanalyzer (Shimadzu, 
Kyoto, Japan). NEBNext Poly(A) mRNA Magnetic Isolation Module was used to enrich mRNA from 1 μg of total 
RNA. We used the NEBNext Ultra Directional RNA Library Prep Kit for Illumina (San Diego, USA) to generate 
barcoded libraries. Libraries were quantified on the MultiNA bioanalyzer (Shimadzu) and pooled to equimolar 
ratios for sequencing. Cluster generation was performed at a concentration of 10 pM (TruSeq SR Cluster Kit 
v3-cBot-HS) and the flow cell was run on Illumina HiSeq2500 generating 50 nt reads at AGRF Melbourne. 
Sequence data has been deposited to NCBI Gene Expression Omnibus under accession number GSE109140.
Bioinformatics analysis. mRNA-seq data processing: Low quality bases (Qscore < 20) were removed 
from the 3′ end with FASTX Toolkit v0.0.13. Trimmed reads less than 20 nt were also discarded. The human 
genome sequence and annotation (GRCh37.75) set were downloaded from the Ensembl website (www.ensem 
bl.org/info/data/ftp). Reads were aligned using STAR version 2.3.1p_r35983. Sorted bam files were generated 
with  SamTools84 (version 0.1.19-44428cd). A gene expression count matrix was generated with featureCounts 
v1.4.285 using a map quality threshold of 10. Genes with an average of fewer than 10 reads per sample were omit-
ted from downstream analysis. EdgeR version 3.6.8 and limma version 3.20.9 were used to perform statistical 
 analysis86. False discovery rate-controlled p values (FDR) ≤ 0.05 were considered significant. Gene expression of 
pathways was analyzed with GSEA-P using the classic  mode87. A differential abundance score was obtained for 
each gene by dividing the sign of the fold change by the log10(p value). This score was used to rank genes from 
most up-regulated to most down-regulated as described  previously23. Curated gene sets were downloaded from 
 MSigDB88. To understand the correlation between effects of VPA and hyperglycaemia on global gene expression, 
we generated a rank–rank density plot of each detected gene. Genes were ranked as above and plotted using the 
filled contour plot function in R. Significance of two-dimensional enrichment of gene sets away from a uniform 
distribution was calculated Manova test of ranks in R as described  previously89.
Reverse transcriptase quantitative PCR. To validate some differentially expressed genes from the 
RNA-seq findings, we repeated the experiment using the same conditions of cell culture and treatment, isolated 
total RNA using the RNeasyMini Kit (Qiagen, Hilden, Germany) and prepared cDNA using the High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Waltham, MA). Real-time PCR was performed using 
an Applied Biosystems 7500 Real Time PCR system following standard protocols and TaqManGene Expres-
sion assays (Applied Biosystems) for complement (MASP2 (Hs00373722_m1), C3 (Hs00163811_m1) genes. 
Target gene expression was normalized to the expression of H3F3 (Hs02598544_g1) Relative quantification was 
achieved with the comparative 2−ΔΔCt method as described  previously90.
LI‑COR Odyssey H3K9/14ac quantitation. Histones were isolated from HepG2 cells using the acid 
extraction  method91. Proteins were separated using 4–12% gradient SDS-PAGE and transferred into a PVDF 
membranes (Immobilon-FL; Millipore). Blots were probed with primary antibodies specific for acetyl-histone 
H3 (06-599; Millipore), or total H3 (14269; Cell Signaling Technology) overnight at 4 °C. Following incubation 
with primary antibodies, membranes were rinsed and probed with appropriate mouse or rabbit secondary anti-
bodies. Protein bands were visualized and quantified using Odyssey CLx image system (LI-COR Biotechnology).
Chromatin immunoprecipitation (ChIP) qPCR. Chromatin immunoprecipitation was performed 
as previously  described16. Three independent 10-cm plates of HepG2 cells growing under conditions above 
described (LG, LG VPA, HG, HG VPA) were used per immunoprecipitation. Cells were fixed with 1% formal-
dehyde in PBS for 10 min at room temp (RT) and the reaction quenched with glycine at a final concentration of 
0.125 M. Sonicated chromatin was checked and anti-H3K9ac (C5B11 Rabbit mAb #9649, Cell Signaling Tech-
nology) enriched DNA was immunoprecipitated overnight. Soluble immunoprecipitated material was washed 
with a salt buffer sequence and collected. The eluted DNA was subjected to qPCR using specific primers (Inte-
grated DNA Technologies) compared to inputs. The primers used in ChIP PCR are as follows; MASP2 forward 
ACA CAG GTT CAG GCC ACT TC, MASP2 reverse CAC ACC ATG AGG TAG GTG GG; C3 forward GCT GAG 
GGA GGG GAA GTA GA, C3 reverse CCT GAC CCT CCA AGA AGC AG.
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